Document is current
Any future updates will be listed below
-
Authors
Wang, Jiayu
Zhang, Qingyuan https://orcid.org/0000-0001-8116-5293
Li, Huiping
Tong, Zhongsheng
Ouyang, Quchang
Li, Huihui
Teng, Yuee
Wang, Biyun
Sun, Tao
Wang, Jingfen
Li, Wei
Niu, Zhaofeng
Li, Hongsheng
Gong, Chang
Wang, Shu https://orcid.org/0000-0002-8651-4795
Wang, Xinshuai
Wu, Xinhong
Liu, Ning
Yu, Guohua
Liu, Fei
Duan, Xianghui
Wang, Shuya
Meng, Yaping
Wang, Li
Xu, Binghe https://orcid.org/0000-0003-4195-337X
-
Funding
Funding for this research was provided by:
CAMS Innovation Fund for Medical Sciences
National Major Scientific and Technological Special Project for "Significant New Drugs Development"
- License Information
-
More Information
Article History
Received: 11 October 2024
Accepted: 31 March 2025
First Online: 9 April 2025
Change Date: 20 February 2026
Change Type: Update
Change Details: In this article the affiliation details for Jiayu Wang and Binghe Xu were incorrectly given as ‘Department of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China’ but should have been ‘Department of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China’. The original article has been updated.
Competing interests
: F.L., X.H.D., S.Y.W., Y.P.M., and L.W. are employees of Xuanzhu Biopharmaceutical Co., Ltd. B.H.X. reported receiving consulting fees and payment for lectures from AstraZeneca and Novartis outside the submitted work. The remaining authors declare no competing interests.
